Chris Coffin Appointed To Plaintiffs' Steering Committee For Federal Taxotere Litigation

PBC is pleased to announce that its own Chris Coffin has been appointed to the Plaintiffs' Steering Committee that will take the lead on all federal Taxotere litigation for plaintiffs throughout the U.S.

Taxotere, a chemotherapy drug manufactured by Sanofi-Aventis and primarily used to treat breast cancer, is linked to permanent hair loss or "alopecia" in women who were undergoing treatment for breast cancer.

As a member of the Plaintiffs' Steering Committee, Chris will help to lead the efforts of attorneys throughout the U.S. over claims that drugmaker Sanofi-Aventis knew, should have known, or even hid the risks associated with Taxotere and permanent hair loss.

According to plaintiffs' claims, Sanofi-Aventis falsely assured patients that their hair would grow back following chemotherapy. The drugmaker is facing allegations that it should have known that Taxotere had an increased rate of permanent hair loss than other similar drugs that were already on the market.

PBC was one of the first firms in the nation to file a Taxotere lawsuit and is at the forefront of this important litigation. Chris is a leading advocate for patients who did not receive adequate warning of the potential to suffer from the devastating side effect of permanent hair loss from taking Taxotere.

To learn more about Chris Coffin, read additional information here.